title: Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
abstract: We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the euglycemic-hyperinsulinemic clamp technique using artificial pancreas. The plasma levels of TAFI (169.0+/-108.8% versus 103.7+/-52.3%; p<0.001, mean+/-S.D.) and PAI-1 (82.7+/-54.5ng/ml versus 52.9+/-51.7ng/ml; p<0.05) were significantly higher in non-obese type 2 diabetic patients than in normal subjects. Univariate analysis showed that the plasma TAFI levels are significantly and inversely correlated with the glucose infusion rate (GIR) (r=-0.42, p<0.005) in all diabetic patients. Moreover, the plasma levels of TAFI were significantly correlated with fasting plasma glucose levels (r=0.47, p<0.001) and HbA(1c) (r=0.38, p<0.005) in all subjects. The plasma levels of PAI-1 were significantly and proportionally correlated with the visceral fat area (r=0.42, p<0.005) and body mass index (r=0.33, p<0.05). There was no significant correlation between plasma levels of TAFI and PAI-1 (r=0.04). These results show that the plasma levels of TAFI and PAI-1 differently correlate with insulin resistance and visceral fat accumulation, suggesting that different factors are implicated in the plasma elevation of TAFI and PAI-1 in non-obese type 2 diabetes mellitus.
authors.affiliation: Third Department of Internal Medicine, Mie University School of Medicine, Edobashi 2-174, Tsu, Mie 514-8507, Japan.
authors.forename: Nagako
authors.initials: N
authors.lastname: Kitagawa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yano
authors.forename: Esteban C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: Nelson E
authors.initials: NE
authors.lastname: Bruno
authors.forename: Rika
authors.initials: R
authors.lastname: Araki
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Akira
authors.initials: A
authors.lastname: Katsuki
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Hori
authors.forename: Kaname
authors.initials: K
authors.lastname: Nakatani
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Sumida
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Adachi
mesh_terms: D015992:Body Mass Index; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000033:anatomy & histology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000378:metabolism
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D025901:Carboxypeptidase B2